Ophthotech Corp (OPHT) 52.35 $OPHT
AVEO Upgraded to Strong Buy, Add to Your Portfolio - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 14, 3:02PM CDT
On Apr 14, Zacks Investment Research upgraded AVEO Pharmaceuticals, Inc. (AVEO) to a Zacks Rank #1 (Strong Buy); is it in your portfolio?
CBM: 42.07 (-0.65), OPHT: 52.35 (+1.09), AVEO: 2.04 (+0.12), AMGN: 169.10 (+0.64)
3 Little-Known Biotechs Working On Potential Blockbusters
Todd Campbell, The Motley Fool - Motley Fool - Sat Mar 28, 12:08PM CDT
Biotech stocks are prone to jaw-dropping pops and drops, caused by even the hint of positive or negative news surrounding drugs in their pipelines. That makes biotech one of the riskiest industries for investors. However, for those willing to take on...
ESPR: 100.53 (-2.60), PFE: 34.93 (+0.04), OPHT: 52.35 (+1.09), PRTA: 36.96 (+0.36), REGN: 472.63 (+9.41), NVS: 103.45 (-0.62)
Ophthotech earns $50M Fovista milestone from Novartis
Seeking Alpha - at Seeking Alpha - Tue Mar 10, 6:48AM CDT
OPHT: 52.35 (+1.09), NVS: 103.45 (-0.62)
InsiderInsights.com Daily Round Up 3/9/15: DRRX, FANG, AXDX, RDUS
InsiderInsights - at Seeking Alpha - Tue Mar 10, 6:34AM CDT
STR: 23.95 (unch), NLSN: 46.10 (+0.27), VOYA: 43.01 (+0.42), NOC: 162.08 (-0.41), ARI: 17.05 (-0.05), OPHT: 52.35 (+1.09), WETF: 21.04 (-0.52), EVI: 3.35 (-0.09), MLNK: 3.75 (unch), DRRX: 2.19 (+0.10), RDUS: 41.90 (-0.48), AXDX: 23.62 (+0.10), HLX: 16.75 (+0.16), FANG: 81.98 (-0.83), FOXF: 15.28 (-0.13), SYK: 96.45 (+1.74), EHTH: 11.44 (+0.07)
Ophthotech Corporation Achieves Second $50 Million Enrollment Milestone under Ex-US Licensing and Commercial Agreement with Novartis for Fovista(R)
Business Wire - Tue Mar 10, 6:00AM CDT
Ophthotech Corporation (Nasdaq:OPHT) today announced that it has achieved a second $50 million enrollment milestone from Novartis Pharma AG as part of the ex-US licensing and commercialization agreement between the two companies focused on the treatment of wet age-related macular degeneration (AMD). This second enrollment milestone from Novartis was triggered as a result of Ophthotech reaching the second enrollment goal under the agreement in its pivotal, multi-national Fovista(R) Phase 3 clinical program. To date, Ophthotech has attained $300 million in upfront fees and milestone payments. These amounts consist of a $200 million upfront fee upon the execution of the agreement in May of last year and $100 million of $130 million in potential enrollment-based milestones under the agreement. Fovista(R), Ophthotech's anti-platelet-derived growth factor (PDGF) compound, is being studied in combination with anti-vascular endothelial growth factor (VEGF) therapy for the treatment of wet AMD.
OPHT: 52.35 (+1.09), NVS: 103.45 (-0.62)
3 Little-Known Stocks I'm Glad I Bought
Todd Campbell, The Motley Fool - Motley Fool - Sun Mar 08, 12:04PM CDT
Source: Flickr user stockmonkeys.com. Investing in clinical-stage biotech stocks isn't for the faint of heart. The industry's jaw-dropping pops and drops can be so dramatic as to suit these stocks only the most speculative portion of an investor's...
JNJ: 100.43 (+0.13), INSY: 62.10 (+0.76), PTLA: 38.48 (-0.47), PFE: 34.93 (+0.04), OPHT: 52.35 (+1.09), BMY: 66.60 (-0.21), REGN: 472.63 (+9.41), NVS: 103.45 (-0.62)
2 Tiny Biotechs That Could Have Blockbuster Opportunity
Todd Campbell and Michael Douglass, The Motley Fool - Motley Fool - Sat Mar 07, 9:11AM CST
Smaller health care stocks are not for the faint of heart. When it comes to developing and testing new drugs, the success rate is tiny but the rewards can be huge. How can the risk-tolerant Fool spot the next Amgen or Biogen ? This health care...
JNJ: 100.43 (+0.13), BIIB: 423.57 (+1.46), PTLA: 38.48 (-0.47), PFE: 34.93 (+0.04), OPHT: 52.35 (+1.09), AMGN: 169.10 (+0.64), BMY: 66.60 (-0.21), NVS: 103.45 (-0.62), CELG: 115.54 (+0.72)
Ophthotech Corporation to Present at the Barclays Global Healthcare Conference
Business Wire - Tue Mar 03, 6:30AM CST
Ophthotech Corporation (NASDAQ:OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the Barclays Capital Global Healthcare Conference in Miami on Tuesday, March 10, 2015 at 9:30 a.m. EST.
OPHT: 52.35 (+1.09)
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Pipeline Review 2015: 41 Companies
M2 - Tue Mar 03, 5:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/pk77s7/wet_neovascular) has announced the addition of the "Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alcon, Inc. - Allergan, Inc. - AlphaMab Co., Ltd - Amakem NV - Avalanche Biotechnologies, Inc. - Bayer AG - BIOCAD - Boehringer Ingelheim GmbH - Charlesson LLC. - Circadian Technologies Limited - Clearside BioMedical, Inc. - EyeCyte, Inc. - F. Hoffmann-La Roche Ltd. - Genzyme Corporation - GlaxoSmithKline plc - iCo Therapeutics Inc. - Icon Bioscience, Inc. - Iconic Therapeutics, Inc. - Intas Pharmaceuticals Ltd. - Kala Pharmaceuticals, Inc. - Lpath, Inc. - Mesoblast Limited - Neurotech Pharmaceuticals, Inc. - Novartis AG - Ohr Pharmaceutical Inc. - Ophthotech Corp. - Oxford BioMedica plc - PanOptica, Inc. - Pfenex Inc. - Pfizer Inc. For more information visit http://www.researchandmarkets.com/research/pk...eovascular
PFE: 34.93 (+0.04), OPHT: 52.35 (+1.09), GSK: 46.57 (-0.67), PFNX: 15.12 (+0.42), LPTN: 2.26 (unch), AGN: 240.22 (+2.88), AAVL: 38.93 (-0.42), OHRP: 2.72 (+0.08), NVS: 103.45 (-0.62)
Ophthotech's (OPHT) CEO Dr. David Guyer on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Feb 23, 9:24PM CST
OPHT: 52.35 (+1.09)
Celgene Gains on Label Expansion of Revlimid in the EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 23, 5:20PM CST
Celgene Corporation announced that Revlimid has received approval from the European Commission for the treatment of adults with previously untreated multiple myeloma who are not eligible for transplant.
CYTK: 7.29 (-0.09), BMRN: 121.08 (-0.16), OPHT: 52.35 (+1.09), CELG: 115.54 (+0.72)
Ophthotech reports 4Q loss
Automated Insights - Mon Feb 23, 3:52PM CST
NEW YORK (AP) _ Ophthotech Corp. (OPHT) on Monday reported a loss of $35.9 million in its fourth quarter.
OPHT: 52.35 (+1.09)
Ophthotech misses by $0.49, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Feb 23, 3:12PM CST
OPHT: 52.35 (+1.09)
Celgene Up on Hematology Drug Revlimid's Label Expansion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 20, 1:30PM CST
Celgene Corporation (CELG) announced that the FDA has expanded the existing indication for Revlimid.
CYTK: 7.29 (-0.09), BMRN: 121.08 (-0.16), OPHT: 52.35 (+1.09), CELG: 115.54 (+0.72)
Coronado Biosciences In-Licenses Revogenex's Pain Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 19, 11:20AM CST
Coronado Biosciences (CNDO) exclusively licensed a late-stage intravenous (IV) formulation of tramadol for the U.S. market from a privately held pharmaceutical company, Revogenex Ireland Ltd.
CYTK: 7.29 (-0.09), BMRN: 121.08 (-0.16), CNDO: 4.09 (-0.09), OPHT: 52.35 (+1.09)
Ophthotech Corporation to Announce Fourth Quarter and Full Year 2014 Financial Results and Host Conference Call on Monday, February 23, 2015
Business Wire - Wed Feb 18, 3:05PM CST
Ophthotech Corporation (Nasdaq:OPHT) today announced that its fourth quarter and year ended December 31, 2014 financial results will be released on Monday, February 23, 2015. Following the announcement, Ophthotech's management will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company's financial results and provide a general business update.
OPHT: 52.35 (+1.09)
Alnylam Reports Narrower Loss in Q4, Focuses on Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 7:19AM CST
Alnylam's (ALNY) fourth-quarter 2014 loss of 28 cents per share was much narrower than the Zacks Consensus Estimate of a loss of 66 cents and the year-ago loss of 51 cents per share.
MON: 116.87 (-0.41), ALNY: 118.00 (-2.70), MDCO: 27.84 (+0.25), OPHT: 52.35 (+1.09)
Genomic Health Loss Narrower than Expected, Revenues Lag - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 9:06AM CST
Genomic Health (GHDX) delivered mixed financial numbers in fourth-quarter 2014 with bottom-line beat but revenue miss.
BMRN: 121.08 (-0.16), OPHT: 52.35 (+1.09), GHDX: 30.59 (-0.10), AFFX: 12.57 (-0.13)
Alkermes Reports Positive Data on Multiple Sclerosis Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 3:20PM CST
Alkermes (ALKS) reported positive top-line data from an early-stage study on its experimental multiple sclerosis treatment, ALKS 8700.
BIIB: 423.57 (+1.46), OPHT: 52.35 (+1.09), PRTA: 36.96 (+0.36), ALKS: 62.60 (-0.24)
AMAG's Q4 Loss Narrows Y/Y, Reiterates 2015 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 9:30AM CST
AMAG Pharmaceuticals (AMAG) reported a fourth-quarter 2014 loss of 2 cents per share, narrower than the year-ago loss of 17 cents per share.
OPHT: 52.35 (+1.09), AMAG: 57.68 (+0.47), PRTA: 36.96 (+0.36)
AVEO Upgraded to Strong Buy, Add to Your Portfolio - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 14, 3:02PM CDT
On Apr 14, Zacks Investment Research upgraded AVEO Pharmaceuticals, Inc. (AVEO) to a Zacks Rank #1 (Strong Buy); is it in your portfolio?
CBM: 42.07 (-0.65), OPHT: 52.35 (+1.09), AVEO: 2.04 (+0.12), AMGN: 169.10 (+0.64)
3 Little-Known Biotechs Working On Potential Blockbusters
Todd Campbell, The Motley Fool - Motley Fool - Sat Mar 28, 12:08PM CDT
Biotech stocks are prone to jaw-dropping pops and drops, caused by even the hint of positive or negative news surrounding drugs in their pipelines. That makes biotech one of the riskiest industries for investors. However, for those willing to take on...
ESPR: 100.53 (-2.60), PFE: 34.93 (+0.04), OPHT: 52.35 (+1.09), PRTA: 36.96 (+0.36), REGN: 472.63 (+9.41), NVS: 103.45 (-0.62)
Ophthotech earns $50M Fovista milestone from Novartis
Seeking Alpha - at Seeking Alpha - Tue Mar 10, 6:48AM CDT
OPHT: 52.35 (+1.09), NVS: 103.45 (-0.62)
InsiderInsights.com Daily Round Up 3/9/15: DRRX, FANG, AXDX, RDUS
InsiderInsights - at Seeking Alpha - Tue Mar 10, 6:34AM CDT
STR: 23.95 (unch), NLSN: 46.10 (+0.27), VOYA: 43.01 (+0.42), NOC: 162.08 (-0.41), ARI: 17.05 (-0.05), OPHT: 52.35 (+1.09), WETF: 21.04 (-0.52), EVI: 3.35 (-0.09), MLNK: 3.75 (unch), DRRX: 2.19 (+0.10), RDUS: 41.90 (-0.48), AXDX: 23.62 (+0.10), HLX: 16.75 (+0.16), FANG: 81.98 (-0.83), FOXF: 15.28 (-0.13), SYK: 96.45 (+1.74), EHTH: 11.44 (+0.07)
Ophthotech Corporation Achieves Second $50 Million Enrollment Milestone under Ex-US Licensing and Commercial Agreement with Novartis for Fovista(R)
Business Wire - Tue Mar 10, 6:00AM CDT
Ophthotech Corporation (Nasdaq:OPHT) today announced that it has achieved a second $50 million enrollment milestone from Novartis Pharma AG as part of the ex-US licensing and commercialization agreement between the two companies focused on the treatment of wet age-related macular degeneration (AMD). This second enrollment milestone from Novartis was triggered as a result of Ophthotech reaching the second enrollment goal under the agreement in its pivotal, multi-national Fovista(R) Phase 3 clinical program. To date, Ophthotech has attained $300 million in upfront fees and milestone payments. These amounts consist of a $200 million upfront fee upon the execution of the agreement in May of last year and $100 million of $130 million in potential enrollment-based milestones under the agreement. Fovista(R), Ophthotech's anti-platelet-derived growth factor (PDGF) compound, is being studied in combination with anti-vascular endothelial growth factor (VEGF) therapy for the treatment of wet AMD.
OPHT: 52.35 (+1.09), NVS: 103.45 (-0.62)
3 Little-Known Stocks I'm Glad I Bought
Todd Campbell, The Motley Fool - Motley Fool - Sun Mar 08, 12:04PM CDT
Source: Flickr user stockmonkeys.com. Investing in clinical-stage biotech stocks isn't for the faint of heart. The industry's jaw-dropping pops and drops can be so dramatic as to suit these stocks only the most speculative portion of an investor's...
JNJ: 100.43 (+0.13), INSY: 62.10 (+0.76), PTLA: 38.48 (-0.47), PFE: 34.93 (+0.04), OPHT: 52.35 (+1.09), BMY: 66.60 (-0.21), REGN: 472.63 (+9.41), NVS: 103.45 (-0.62)
2 Tiny Biotechs That Could Have Blockbuster Opportunity
Todd Campbell and Michael Douglass, The Motley Fool - Motley Fool - Sat Mar 07, 9:11AM CST
Smaller health care stocks are not for the faint of heart. When it comes to developing and testing new drugs, the success rate is tiny but the rewards can be huge. How can the risk-tolerant Fool spot the next Amgen or Biogen ? This health care...
JNJ: 100.43 (+0.13), BIIB: 423.57 (+1.46), PTLA: 38.48 (-0.47), PFE: 34.93 (+0.04), OPHT: 52.35 (+1.09), AMGN: 169.10 (+0.64), BMY: 66.60 (-0.21), NVS: 103.45 (-0.62), CELG: 115.54 (+0.72)
Ophthotech Corporation to Present at the Barclays Global Healthcare Conference
Business Wire - Tue Mar 03, 6:30AM CST
Ophthotech Corporation (NASDAQ:OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the Barclays Capital Global Healthcare Conference in Miami on Tuesday, March 10, 2015 at 9:30 a.m. EST.
OPHT: 52.35 (+1.09)
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Pipeline Review 2015: 41 Companies
M2 - Tue Mar 03, 5:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/pk77s7/wet_neovascular) has announced the addition of the "Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alcon, Inc. - Allergan, Inc. - AlphaMab Co., Ltd - Amakem NV - Avalanche Biotechnologies, Inc. - Bayer AG - BIOCAD - Boehringer Ingelheim GmbH - Charlesson LLC. - Circadian Technologies Limited - Clearside BioMedical, Inc. - EyeCyte, Inc. - F. Hoffmann-La Roche Ltd. - Genzyme Corporation - GlaxoSmithKline plc - iCo Therapeutics Inc. - Icon Bioscience, Inc. - Iconic Therapeutics, Inc. - Intas Pharmaceuticals Ltd. - Kala Pharmaceuticals, Inc. - Lpath, Inc. - Mesoblast Limited - Neurotech Pharmaceuticals, Inc. - Novartis AG - Ohr Pharmaceutical Inc. - Ophthotech Corp. - Oxford BioMedica plc - PanOptica, Inc. - Pfenex Inc. - Pfizer Inc. For more information visit http://www.researchandmarkets.com/research/pk...eovascular
PFE: 34.93 (+0.04), OPHT: 52.35 (+1.09), GSK: 46.57 (-0.67), PFNX: 15.12 (+0.42), LPTN: 2.26 (unch), AGN: 240.22 (+2.88), AAVL: 38.93 (-0.42), OHRP: 2.72 (+0.08), NVS: 103.45 (-0.62)
Ophthotech's (OPHT) CEO Dr. David Guyer on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Feb 23, 9:24PM CST
OPHT: 52.35 (+1.09)
Celgene Gains on Label Expansion of Revlimid in the EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 23, 5:20PM CST
Celgene Corporation announced that Revlimid has received approval from the European Commission for the treatment of adults with previously untreated multiple myeloma who are not eligible for transplant.
CYTK: 7.29 (-0.09), BMRN: 121.08 (-0.16), OPHT: 52.35 (+1.09), CELG: 115.54 (+0.72)
Ophthotech reports 4Q loss
Automated Insights - Mon Feb 23, 3:52PM CST
NEW YORK (AP) _ Ophthotech Corp. (OPHT) on Monday reported a loss of $35.9 million in its fourth quarter.
OPHT: 52.35 (+1.09)
Ophthotech misses by $0.49, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Feb 23, 3:12PM CST
OPHT: 52.35 (+1.09)
Celgene Up on Hematology Drug Revlimid's Label Expansion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 20, 1:30PM CST
Celgene Corporation (CELG) announced that the FDA has expanded the existing indication for Revlimid.
CYTK: 7.29 (-0.09), BMRN: 121.08 (-0.16), OPHT: 52.35 (+1.09), CELG: 115.54 (+0.72)
Coronado Biosciences In-Licenses Revogenex's Pain Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 19, 11:20AM CST
Coronado Biosciences (CNDO) exclusively licensed a late-stage intravenous (IV) formulation of tramadol for the U.S. market from a privately held pharmaceutical company, Revogenex Ireland Ltd.
CYTK: 7.29 (-0.09), BMRN: 121.08 (-0.16), CNDO: 4.09 (-0.09), OPHT: 52.35 (+1.09)
Ophthotech Corporation to Announce Fourth Quarter and Full Year 2014 Financial Results and Host Conference Call on Monday, February 23, 2015
Business Wire - Wed Feb 18, 3:05PM CST
Ophthotech Corporation (Nasdaq:OPHT) today announced that its fourth quarter and year ended December 31, 2014 financial results will be released on Monday, February 23, 2015. Following the announcement, Ophthotech's management will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company's financial results and provide a general business update.
OPHT: 52.35 (+1.09)
Alnylam Reports Narrower Loss in Q4, Focuses on Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 7:19AM CST
Alnylam's (ALNY) fourth-quarter 2014 loss of 28 cents per share was much narrower than the Zacks Consensus Estimate of a loss of 66 cents and the year-ago loss of 51 cents per share.
MON: 116.87 (-0.41), ALNY: 118.00 (-2.70), MDCO: 27.84 (+0.25), OPHT: 52.35 (+1.09)
Genomic Health Loss Narrower than Expected, Revenues Lag - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 9:06AM CST
Genomic Health (GHDX) delivered mixed financial numbers in fourth-quarter 2014 with bottom-line beat but revenue miss.
BMRN: 121.08 (-0.16), OPHT: 52.35 (+1.09), GHDX: 30.59 (-0.10), AFFX: 12.57 (-0.13)
Alkermes Reports Positive Data on Multiple Sclerosis Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 3:20PM CST
Alkermes (ALKS) reported positive top-line data from an early-stage study on its experimental multiple sclerosis treatment, ALKS 8700.
BIIB: 423.57 (+1.46), OPHT: 52.35 (+1.09), PRTA: 36.96 (+0.36), ALKS: 62.60 (-0.24)
AMAG's Q4 Loss Narrows Y/Y, Reiterates 2015 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 9:30AM CST
AMAG Pharmaceuticals (AMAG) reported a fourth-quarter 2014 loss of 2 cents per share, narrower than the year-ago loss of 17 cents per share.
OPHT: 52.35 (+1.09), AMAG: 57.68 (+0.47), PRTA: 36.96 (+0.36)
